Cardiovascular Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Students' Scientific Research Center (SSRC), Tehran University of Medical Sciences, Tehran, Iran.
Curr Probl Cardiol. 2022 Oct;47(10):100992. doi: 10.1016/j.cpcardiol.2021.100992. Epub 2021 Sep 24.
For more than 2 years, health care systems have been floundering in a massive crisis of coronavirus disease 2019 (COVID-19) pandemic. While acute respiratory distress syndrome is the main complication in patients with COVID-19, as the pandemic continues, more data about the nonrespiratory effects of the coronavirus is obtained, including developing Coagulopathy-related manifestations, in the form of venous and arterial thromboembolism. Although arterial thrombosis a rare complication of this disease, it proves to be an effective factor in the mortality and morbidity of COVID-19 patients. The pathophysiology of thrombosis reveals a complex relation between hemostasis and immune system that can be disrupted by COVID-19. Thrombectomy, anticoagulant therapy, and thrombolysis are the main treatments in these patients. In addition, appropriate thromboprophylaxis treatment should be considered in COVID-19 patients. In this article, we have successfully reviewed the arterial thrombotic events in patients reported around the world, including the diagnostic and management method of choice.
两年来，医疗保健系统一直在 2019 冠状病毒病（COVID-19）大流行的巨大危机中苦苦挣扎。虽然急性呼吸窘迫综合征是 COVID-19 患者的主要并发症，但随着大流行的继续，关于冠状病毒非呼吸作用的更多数据被获得，包括以静脉和动脉血栓栓塞的形式出现的凝血功能障碍相关表现。尽管动脉血栓形成是这种疾病的罕见并发症，但它被证明是 COVID-19 患者死亡率和发病率的一个有效因素。血栓形成的病理生理学揭示了止血和免疫系统之间的复杂关系，COVID-19 可以破坏这种关系。取栓术、抗凝治疗和溶栓是这些患者的主要治疗方法。此外，COVID-19 患者应考虑适当的血栓预防治疗。在本文中，我们成功地回顾了世界各地报告的患者的动脉血栓性事件，包括首选的诊断和治疗方法。
